Current Status of Marine-Derived Compounds as Warheads in Anti-Tumor Drug Candidates
In this review, we have attempted to describe all of the antibody–drug conjugates using a marine-derived compound as the “warhead”, that are currently in clinical trials as listed in the current version of the NIH clinical trials database (clinicaltrials.gov). In searching this database, we used the...
Main Authors: | David J. Newman, Gordon M. Cragg |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2017-03-01
|
Series: | Marine Drugs |
Subjects: | |
Online Access: | http://www.mdpi.com/1660-3397/15/4/99 |
Similar Items
-
Marine-Sourced Anti-Cancer and Cancer Pain Control Agents in Clinical and Late Preclinical Development
by: David J. Newman, et al.
Published: (2014-01-01) -
The “Utility” of Highly Toxic Marine-Sourced Compounds
by: David J. Newman
Published: (2019-05-01) -
Antibody Conjugates for Targeted Therapy Against HIV-1 as an Emerging Tool for HIV-1 Cure
by: Jeffrey C. Umotoy, et al.
Published: (2021-07-01) -
Antibody drug conjugates (ADC) : Current status and mapping of ADC:s in clinical programs
by: Congreve, Samantha, et al.
Published: (2018) -
Antibody–drug conjugates in solid tumors: a look into novel targets
by: Carmen Criscitiello, et al.
Published: (2021-01-01)